Drug profile · INN
abametapir
XEGLYZE
abametapir (XEGLYZE) is a copper sequestering agent. Route of administration: topical. Current US regulatory status: approved.
FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — abametapir
- US status
- approved
- Class
- —
- Route
- TOPICAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
abametapir (XEGLYZE) is a copper sequestering agent. Route of administration: topical. Current US regulatory status: approved.
Key facts
INN abametapir
Brand XEGLYZE
Mechanism Copper sequestering agent
Target Copper
Route TOPICAL
Formulation LOTION
Mechanism of action
Copper sequestering agent
Primary target: Copper
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is abametapir?
abametapir (XEGLYZE) is a copper sequestering agent. Route of administration: topical. Current US regulatory status: approved.
What is the brand name for abametapir?
XEGLYZE is a marketed brand name for abametapir. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of abametapir?
abametapir has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.